Mabion S.A.

Warsaw Stock Exchange:MAB.WA

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

Location

Poland

Market Cap

USD 42.51 M

Share Price

USD 2.63

Avg Daily Volume

42,990

Change (1 day)

0.80%

Change (1 year)

-39.12%

Change (YTD)

21.67%

Mabion S.A. Dividend Yield on June 13, 2025: 0.00%

Mabion S.A. Dividend Yield is 0.00% on June 13, 2025. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.

Mabion S.A. 52-week low Dividend Yield is 0.00% on June 13, 2025, which is NA below the current Dividend Yield.
Mabion S.A. 52-week low Dividend Yield is 0.00% on June 13, 2025, which is NA below the current Dividend Yield.
Mabion S.A. average Dividend Yield for the last 52 weeks is 0.00%.

Daily

From:

To:

Zoom:

Key data

Date	Dividend Yield	Market Capitalization	Share Price	Share Price

Warsaw Stock Exchange: MAB.WA

Mabion S.A.

CEO	Mr. Krzysztof Kaczmarczyk
IPO Date	Aug. 10, 2010
Location	Poland
Headquarters	ul. gen. Mariana Langiewicza 60
Employees	206
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies

Description

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.